{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:57:21Z","timestamp":1791644241839,"version":"4.3.4"},"reference-count":7,"publisher":"Baishideng Publishing Group Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Methodol"],"abstract":"<jats:p>Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder affecting over 2% of the global population, marked by social communication deficits and repetitive behaviors. Kabatas et al  explored the efficacy and safety of Wharton\u2019s jelly-derived mesenchymal stem cell (WJ-MSC) therapy in a 4-year-old child with ASD. Using the childhood autism rating scale and Denver II developmental screening test, significant improvements were seen after six WJ-MSC sessions, with no adverse events over 2 years. Despite promising results, the study\u2019s single-case design limits generalizability. Larger, multi-center trials are needed to validate the findings and assess long-term effects of WJ-MSC therapy in ASD.<\/jats:p>","DOI":"10.5662\/wjm.v15.i2.100074","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T02:55:11Z","timestamp":1732676111000},"source":"Crossref","is-referenced-by-count":4,"title":["Evaluating Wharton\u2019s jelly-derived stem cell therapy in autism: Insights from a case study"],"prefix":"10.5662","volume":"15","author":[{"given":"Muzamil","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulqadir J","family":"Nashwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","unstructured":"CiNii.   Diagnostic and Statistical Manual of Mental Disorders. [cited 27 September 2024]. Available from: https:\/\/cir.nii.ac.jp\/crid\/1573950399819987840"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1550151"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00304"},{"key":"B4","unstructured":"Szachta P, Skonieczna-\u017bydecka K, Adler G, Karakua-Juchnowicz H, Madlani H, Igny\u015b I. Immune related factors in pathogenesis of autism spectrum disorders. Eur Rev Med Pharmacol Sci 2016; 20: 3060-3072"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2020.03.011"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-021-10257-0"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v16.i6.641"}],"container-title":["World Journal of Methodology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2222-0682\/full\/v15\/i2\/100074.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2222-0682\/full\/v15\/i2\/100074.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T02:55:52Z","timestamp":1732676152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2222-0682\/full\/v15\/i2\/100074.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":7,"journal-issue":{"issue":"2"},"alternative-id":["100074"],"URL":"https:\/\/doi.org\/10.5662\/wjm.v15.i2.100074","relation":{},"ISSN":["2222-0682"],"issn-type":[{"value":"2222-0682","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}